A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
A phase 3 trial of BGB-16673, Bendamustine, Rituximab, Chlorambucil and Obinutuzumab in chronic lymphocytic leukaemia, run by BeOne Medicines, active and no longer recruiting.
Overview
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors is a phase 3 interventional study registered as NCT06970743 by BeOne Medicines, with 153 participants enrolled, started 2025-05-29 and due to reach its primary completion in 2029-11-30. Interventions recorded: BGB-16673, Bendamustine, Rituximab, Methylprednisolone, Chlorambucil and Obinutuzumab.
Similar pages
not linked directly; found by shared links- TrialA Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Shares Bendamustine, BeOne Medicines (formerly BeiGene), Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Shares Obinutuzumab, BeOne Medicines (formerly BeiGene), Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialStudy of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
Shares Chlorambucil, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Shares Bendamustine, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Shares Bendamustine, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Shares Bendamustine, Obinutuzumab, Rituximab and the tag pipeline.
- TrialA Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Shares Bendamustine, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialStudy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Shares Obinutuzumab, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.